<DOC>
	<DOCNO>NCT02475161</DOCNO>
	<brief_summary>The purpose study assess effect daily administration rabeprazole single-dose pharmacokinetics JNJ-42847922 healthy participant .</brief_summary>
	<brief_title>A Study Investigate Effect Increased Gastric pH Oral Bioavailability Orexin-2 Receptor Antagonist JNJ-42847922 Healthy Participants</brief_title>
	<detailed_description>This open-label , single-center , fixed-sequence study design assess effect multiple oral administration rabeprazole ( PPI ) pharmacokinetics single oral dose JNJ-42847922 healthy participant . The study consist 3 phase : Screening Phase approximately 4 week ( Days -29 -2 ) ; Open Label Treatment Phase ( Days -1 7 ) ; End-of-Study Phase occur 7 14 day last dose study drug . All participant receive JNJ-42847922 , orally Day 1 ( alone ) Day 6 ( along rabeprazole ) .Rabeprazole administer orally Day 2 Day 6 . Pharmacokinetics primarily JNJ-42847922 , M12 metabolite M16 metabolite . Participant 's safety monitor throughout study .</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>If woman , must postmenopausal ( spontaneous menses least 2 year ) surgically sterile ( include limit hysterectomy , oophorectomy , salpingectomy , tubal ligation , tubal occlusion ) . Women must agree donate egg ( ovum , oocytes ) study 3 month last dose study drug . Women childbearing potential currently breastfeed child allow participate study If man , must agree use adequate contraception method deem appropriate investigator ( e.g. , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Body mass index ( BMI ) ( weight [ kilogram { kg } /height^2 [ meter ] ^2 ) 18 30 kg/m^2 ( inclusive ) , body weight less 50 kg Blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic A participant must nonsmoker Current history gastrointestinal disorder Clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic disease , infection , hypertension vascular disorder , kidney urinary tract disturbance , significant psychiatric disorder ( history current diagnosis ) , history epilepsy fit unexplained blackout , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry , urinalysis , thyroid stimulate hormone ( TSH ) screen admission study center ( Day 1 ) deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12lead electrocardiogram ( ECG ) screen admission study center ( Day 1 ) deem appropriate investigator Use prescription nonprescription medication , within 7 day first schedule dose study drug ( include vitamin herbal supplement ) , except acetaminophen hormonal replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Rabeprazole</keyword>
	<keyword>JNJ-42847922</keyword>
</DOC>